Mentice AB (publ) (STO:MNTC)
Sweden · Delayed Price · Currency is SEK | Market Cap | 358.60M -22.1% |
| Revenue (ttm) | 279.09M -3.9% |
| Net Income | -32.33M |
| EPS | -1.15 |
| Shares Out | 28.13M |
| PE Ratio | n/a |
| Forward PE | 144.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,794 |
| Average Volume | 18,326 |
| Open | 12.70 |
| Previous Close | 12.70 |
| Day's Range | 12.50 - 12.75 |
| 52-Week Range | 8.50 - 21.30 |
| Beta | 0.48 |
| RSI | 38.72 |
| Earnings Date | Apr 23, 2026 |
About Mentice AB
Mentice AB (publ), together with its subsidiaries, develops, sells, and markets solutions for training and decision support in the clinical area of interventional angiography in cardiology, neurology, vascular surgery, and radiology. It operates through the Mentice VIST, Physical Sim, and Ankyras segments. The company offers virtual simulation products, including VR simulator platforms; procedural learning models; patient simulator accessories and extensions for endovascular therapies; and Angiosuite integrations, such as the VIST virtual patie... [Read more]
Financial Performance
In 2025, Mentice AB's revenue was 279.09 million, a decrease of -3.87% compared to the previous year's 290.33 million. Losses were -32.33 million, 75.5% more than in 2024.
Financial StatementsNews
Mentice AB Transcript: DNB Carnegie Healthcare Seminar 2026
The presentation highlighted strong growth in simulation solutions for minimally invasive procedures, with a broadened customer base and robust financial performance. Strategic investments in advanced training and digital twin technology aim to drive further expansion and profitability.
Mentice AB Earnings Call Transcript: Q4 2025
Q4 saw strong organic growth in sales and order intake, with EBITDA margin rising to 25%. The Americas and MDI segment led performance, while cost control and R&D focus position the company for continued growth in 2026.
Mentice AB Earnings Call Transcript: Q3 2025
Q3 saw 22% year-over-year net sales growth, driven by the medical device industry in Americas and EMEA, with improved EBITDA margin from cost reductions. A successful rights issue and the launch of a portable simulation system support future growth, while hospital and APAC segments face challenges.
Mentice AB Earnings Call Transcript: Q2 2025
Q2 net sales declined 33% year-over-year due to a strong prior-year comparison and cautious market, but cost-saving measures and new product clearances position the business for improved profitability and growth in the second half. Rights issue to raise SEK 32 million is well supported.
Mentice AB Earnings Call Transcript: Q1 2025
Net sales grew 19.5% year-over-year, driven by strong performance in Americas and APAC, while EBITDA was impacted by restructuring and currency effects. Medical device industry order intake surged, but Healthcare Systems lagged and is being addressed.
Mentice AB Earnings Call Transcript: Q4 2024
Q4 2024 delivered 22.4% net sales growth year-over-year, with strong EMEA and APAC performance and a 19.1% EBITDA margin. Full-year sales rose 6%, and software-driven gross margin improvements set a positive outlook for 2025.
Mentice AB Earnings Call Transcript: Q3 2024
Q3 net sales declined 10% year-over-year to SEK 58 million, with APAC growth offset by declines in Americas and EMEA. EBITDA was negative for the quarter but break-even year-to-date, and two major post-quarter orders are expected to support future growth.